Gilead challenges US govt patents on HIV drug Truvada
Gilead Sciences, the maker of HIV drug Truvada, has asked the US Patent and Trademark Office to review patents granted to the government covering preventative use of the drug.
Novo Nordisk seeks to block Mylan generic
Danish pharmaceutical company Novo Nordisk has sued Mylan in a US court over a proposed generic of diabetes drug Victoza (liraglutide).
UK faces medicine shortages after no deal: leaked govt report
A leaked UK government report reveals that a no deal Brexit may result in shortages of medicines and other pharmaceutical products.
Bayer to sell off animal health business for $7.6bn
Bayer has agreed to sell its animal health business to US-based Elanco Animal Health for $7.6 billion, as part of its strategic plan to focus on its core life sciences businesses.
Amneal and others pay $1.5m to settle antitrust suit over Alzheimer’s drug
Amneal and three other generic makers have agreed to pay $1.54 million to settle a class-action lawsuit, which alleged the companies engaged in an unlawful scheme to maintain their monopoly over an Alzheimer’s drug.
EMA and FDA aligned on marketing authorisations: report
The US and Europe have reached the same conclusion in more than 90% of marketing authorisation decisions for new medicines, according to a report from the European Medicines Agency.
Pharma bodies sign NDAs with UK govt over no-deal Brexit plans
Several pharma bodies have signed non-disclosure agreements which prevent them from disclosing the UK government’s plans for a no-deal Brexit.
Fed Circuit majority ‘problematically’ adds new rule in Actavis suit: chief judge
The US Court of Appeals for the Federal Circuit yesterday, August 15, blocked Actavis’s attempt to market a generic version of Nalpropion Pharmaceuticals’ weight-loss drug Contrave.
Sanofi victorious at Fed Circ in prostate cancer drug dispute
Sanofi secured a win at the US Court of Appeals for the Federal Circuit yesterday, August 14, after the appeals court concluded a lower court lacked authority to invalidate claims of a patent covering a prostate cancer drug.
NHS to receive £8m from Aspen over anti-competitive practices
Drugmaker Aspen has offered to pay the UK’s National Health System £8 million to resolve competition concerns.
